Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 11/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856064 | 0.80 | BRAF (0.44) | BRAFRAB9A | |
| SCHEMBL29261674 | 0.68 | LMNA (0.44) | ACACAMEN1ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL2858259 | 0.67 | CLK1 (0.51) | BRAFRAB9A | |
| SCHEMBL2856446 | 0.65 | DYRK1A (0.46) | BRAFRAB9A | |
| SCHEMBL14949680 | 0.63 | MET (0.44) | ALDH1A1RAB9AMAP4K4 | |
| SCHEMBL2853481 | 0.63 | EPHX2 (0.41) | BRAFMEN1ALDH1A1RAB9A | |
| SCHEMBL2854440 | 0.63 | ROCK2 (0.48) | BRAFROCK2MEN1RAB9A | |
| SCHEMBL2859799 | 0.63 | ROCK2 (0.44) | BRAFROCK2RAB9A | |
| SCHEMBL1258338 | 0.63 | BRAF (0.56) | BRAFMEN1ALDH1A1RAB9A | |
| SCHEMBL202304 | 0.62 | NPC1 (0.39) | MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885ROCK2 402/4885ACACB 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.